iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019
A2a Inhibitor TIGIT

iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019

Gosselies, Belgium and Cambridge, MA – March 29, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it will present data on the efficacy of its innovative and differentiated A2A receptor antagonist, EOS100850, as well as its human antibody directed against TIGIT, EOS884448, in eight posters at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2019, taking place from March 29 - April 3, 2019 in Atlanta, Georgia. 

“We continue to be excited by the preclinical data from our two immuno-oncology programs, both of which promise mono- and combination therapy potential with other anti-cancer treaments,” said Michel Detheux, President and Chief Executive Officer of iTeos Therapeutics. “The preclinical data being presented at AACR demonstrate key differentiation of our A2A receptor antagonist, such as unique prolonged effects of high potency within the adenosine-rich tumor microenvironment and anti-tumor activity in several cancer models and with different drug combinations. The data also provide a deeper understanding of the adenosine pathway in solid tumors. Additionally, our research on the TIGIT activation pathway sheds light on promising strategies to restore anti-tumor immunity.” 

The details of the poster presentations are as follows:

Title: EOS100850, a non-brain penetrant highly selective A2A receptor antagonist, uniquely maintains high potency within the adenosine rich tumor microenvironment 
Session: Novel Immunomodulatory Agents 1
Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET
Authors: Erica Houthuys, et al.
Location: Section 25, Poster 3261

Title: EOS100850 potently restores adenosine A2A receptor-dependent suppression of T cell function in the adenosine rich tumor microenvironment 
Session: Novel Immunomodulatory Agents 1 
Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET
Authors: Erica Houthuys, et al.
Location: Section 25, Poster 3278 

Title: Extensive characterization of the adenosine pathway in human solid tumors gives a hint on cancer indication selection for the A2A receptor antagonist EOS100850.
Session: Novel Immunomodulatory Agents 2
Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET
Authors: Veronique Bodo, et al. 
Location: Section 25, Poster 4149 

Title: EOS100850 inhibits A2A receptor signaling in human whole blood: two pharmacodynamic assays to monitor EOS100850 activity in clinical studies.
Session: Novel Immunomodulatory Agents 2
Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET
Authors: Veronique Bodo, et al.
Location: Section 25, Poster 4154

Title: EOS100850, an A2A receptor antagonist with prolonged pharmacodynamic activity, mediates the generation of specific durable immune responses in a murine breast cancer model 
Session: Novel Immunomodulatory Agents 2
Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET
Authors: Grégory Driessens, et al. 
Location: Section 25, Poster 4147 

Title: EOS884448, a high affinity fully human antibody directed against TIGIT, mediates in vitro anti-tumor activity through multiples mechanisms of action involving activation of intratumor effector cells and depletion of regulatory T cells.
Session: Immune Checkpoints 1
Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET
Authors: Catherine Hoofd, et al.
Location: Section 24, Poster 3240

Title: a-TIGIT mediates antitumor activity through multiple mechanisms of action involving activation of intratumor effector T cells and depletion of regulatory T cells 
Session: Immune Checkpoints 1
Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET 
Authors: Grégory Driessens, et al.
Location: Section 24, Poster 3249

Title: TIGIT pathway phenotyping sheds light on promising strategies to restore anti-tumor immunity
Session: Adaptive Immune Cells in the Tumor Microenvironment
Date & Time: Wednesday, April 3, 2019, 8:00 AM - 12:00 PM ET 
Authors: Catherine Hoofd, et al.
Location: Section 23, Poster 4969

Full poster abstracts are available on the AACR conference website at www.aacr.org. 

About iTeos Therapeutics 
iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com.

For further information, please contact:
Michel Detheux, CEO
iTeos Therapeutics
info@iteostherapeutics.com 

Amber Fennell, Mathew Neal, Sukaina Virji
Consilium Strategic Communications
+44 203 709 5700
iteos@consilium-comms.com

Sarah McCabe and Carl Mauch
Stern Investor Relations, Inc.
+ 1 212 362 1200
iTeos@sternir.com 
 

Related news

  • iTeos Therapeutics Announces New  Scientific Advisory Board Members
    A2a Inhibitor Clinical Trials Corporate Research TIGIT

    iTeos Therapeutics Announces New Scientific Advisory Board Members

    Gosselies, Belgium and Cambridge, MA – September 9th, 2019 – iTeos Therapeutics SA (iTeos), a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it has added four new world-leading experts in oncology, immunology, and drug discovery and development to its Scientific Advisory Board (SAB): Gordon Freeman,  William Hahn, Ben Stanger and Matt Vander Heiden. The SAB will support the development of iTeos’ pipeline of clinical and preclinical assets targeting key mechanisms of immunosuppression, in order to transform the lives of people living with cancer. The full SAB comprises: Gordon Freeman, Ph.D, Researcher at Boston’s Dana-Farber Cancer Institute, who will become Chairman of the SAB William C. Hahn, M.D.,Ph.D, Chief Research Strategy Officer at Boston’s Dana-Farber Cancer Institute Ben Z. Stanger, M.D, Professor in Cancer Research at the University of Pennsylvania’s Perelman School of Medicine Matthew G. Vander Heiden, Ph.D., Associate Director at the Massachusetts Institute of Technology’s (MIT) Koch Institute for   Integrative Cancer Research Benoit Van den Eynde M.D., Ph.D, Director of the Brussels Branch of the Ludwig Institute for Cancer Research, Ltd. and co-founder of iTeos and previously Chairman of the SAB, will remain a key member of the SAB Pierre Coulie, M.D., Ph.D. Professor of Immunology, the De Duve Institute of the Université Catholique de Louvain Scott Chappel, Ph.D. Chief Scientific Officer at iTeos Therapeutics Michel Detheux, Ph.D., Chief Executive Officer of iTeos, commented: “By assembling this new Scientific Advisory Board, iTeos gains access to a broad range of expertise and extensive knowledge. As we advance our highly-differentiated pipeline of immunotherapies that target the tumor microenvironment, with the aim of enhancing the anti-tumor immune response and addressing some of the limitations of first-generation immunotherapies, their scientific rigour will be invaluable. “While welcoming the new members of the SAB, I would also like to thank the retiring members including Dr. Jean-Yves Bonnefoy, Prof. Vincenzo Bronte, Prof. Vincenzo Cerundolo, Prof. Douglas Fearon, Dr. Jedd Wolchok and Dr. Thomas Gajewski. Their expertise and guidance have been integral to the growth of iTeos Therapeutics and I wish them all well in their future endeavours.” Gordon Freeman, Chairman of the Scientific Advisory Board of iTeos, commented: “I am delighted to be working with, and chairing, the Scientific Advisory Board at iTeos Therapeutics, an exciting company that I have been aware of for a long time and have followed their progress. iTeos’ pipeline of highly selective and potent drug candidates is one that includes some of the most promising drug candidates targeting the A2A pathway as well as TIGIT, a second-generation immune checkpoint inhibitor that is gaining increased interest from big pharma and will enter the clinic in the second half of 2019. I look forward to advising the team through the next stages of their clinical development.” Additional background on all SAB members can be found on the iTeos website. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, and Catherine London (US) Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics to Present Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR
    A2a Inhibitor TIGIT

    iTeos Therapeutics to Present Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR

    Gosselies, Belgium– April 12, 2018 –iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that it will present data for its A2Aantagonist and anti-TIGIT antibody programs in two abstracts at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place from April 14-18, 2018 in Chicago, IL. “We continue to make good progress advancing our best-in-class A2A receptor antagonist and our promising anti-TIGIT antibody toward the clinic and are delighted to present this data at AACR,” said Michel Detheux, Ph.D., Chief Executive Officer of iTeos.“After the advancement of the A2Areceptor antagonist program into the clinic in 2018, the anti-TIGIT antibody will follow in 2019, fortifying our position as a leading player in the immunotherapy field.” Adenosine A2AReceptor Inhibitor (EOS100850): Best-in-class A2Areceptor antagonistprogram currently being evaluated for safety and efficacy in preclinical models with a Phase I trial expected to begin in 2018. Presentation Title: EOS100850, an insurmountable and non-brain penetrant A2Areceptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and exhibits best-in class characteristics Session Title:Late-Breaking Research: Immunology 2 Session Date and Time:Tuesday, April 17, 2018 from 1:00 PM - 5:00 PM CT Session Location: Poster Section 44 Human Anti-TIGIT Antibody (EOS884448): Antagonist antibody against human TIGIT that demonstrates a classical human IgG pharmacokinetics profile. It is currently being evaluated for safety and efficacy in preclinical models with a Phase I trial expected to begin in 2019. Presentation Title: A TIGIT antagonist antibody EOS884448 shows dual mechanism of action by restoration of T cell effector functions and preferential depletion of Treg Session Title:Late-Breaking Research: Immunology 1 Session Date and Time:Monday, April 16, 2018 from 8:00 AM - 12:00 PM CT Session Location:Poster Section 45 About iTeos’ Adenosine A2AReceptor Inhibitor (EOS100850) The adenosine A2Areceptor is the main adenosine receptor expressed on immune cells, which promotes immune suppression, leading to tumor evasion. iTeos’ best-in-class A2Areceptor antagonist, EOS100850, restores T-cell activation inhibited by adenosine. EOS100850 promotes anti-tumor efficacy in mouse tumor models in combination with several immune-checkpoint inhibitors, retains high potency in the presence of elevated intra-tumoral adenosine concentrations, and is non-brain penetrant. EOS100850 is currently being evaluated for safety and efficacy in preclinical models. About iTeos’ Human Anti-TIGIT Antibody (EOS884448) Tigit is an immunosuppressive receptor expressed on lymphoid cell populations. TIGIT expression increases in cancer patients and marks exhausted T cells. EOS884448 is an antagonist antibody against human TIGIT. Preclinical studies show its potency to restore T cell function and to preferentially deplete Treg cells in cancer patient material. ADCC/ADCP-enabling isotypes of a-TIGIT surrogate Ab show potent monotherapy efficacy in murine tumor models that correlates to increased T cell activation and reduced Treg infiltration of tumors. EOS884448 demonstrates classical human IgG pharmacokinetics profile and a good developability profile. EOS884448 is currently being evaluated for safety and efficacy in preclinical models. About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. The company is currently also evaluating its third program, EOS200271, a clinical-stage potent and selective IDO1 inhibitor. Based in Gosselies, Belgium, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute in 2011, with funds from the LICR, the Walloon Region of Belgium and the European Fund for Economic and Regional Development (FEDER). For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe Stern Investor Relations, Inc. + 1 212 362 1200 sarah@sternir.com

  • iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference
    A2a Inhibitor TIGIT

    iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference

    Two Phase 1 trials to start in 2018 for A2A receptor antagonist and IDO1 inhibitor Gosselies, Belgium – February 9, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that it will present new data for its A2A antagonist and anti-TIGIT antibody programs in two oral presentations at the upcoming Molecular Medicine Tri-Conference 2018, taking place from February 11-16, 2018 in San Francisco, CA. “The preclinical data to be presented further demonstrate the potential of our insurmountable and non-brain penetrant A2A receptor antagonist in combination with immune checkpoints. With our anti-TIGIT antibody program, we saw anti-tumor efficacy and reactivation of T-cells in preclinical models which is encouraging for the potential of this product as a monotherapy, combining immune-modulation and antibody dependent, cell-mediated cytotoxicity,” said Michel Detheux, Ph.D., Chief Executive Officer of iTeos. “Our team's deep experience, along with the commitment and support of our investors, will allow us to pursue an aggressive development strategy for our best-in-class pipeline in the near-term. With full rights to our IDO1 inhibitor back in-house and the advancement of our A2A receptor antagonist program into the clinic in the third quarter, we will have two leading candidates in clinical trials in 2018.” Adenosine A2A Receptor Inhibitor (EOS100850): Best-in-class A2A receptor antagonist program currently being evaluated for safety and efficacy in preclinical models with a Phase I trial expected to begin in 2018. Presentation Title: EOS100850, a Best-in-Class, Insurmountable and Non-Brain Penetrant A2A Receptor Antagonist, Inhibits Adenosine-Mediated T Cell Suppression and Exhibits Anti-Tumor Activity Date & Time: Monday, February 12, 2018 Authors: Grégory Driessens Poster Number: 36 Key Takeaways: EOS100850 potently inhibits A2A receptor in T lymphocytes, at single digit nanomolar concentrations, independently of adenosine concentrations EOS100850 potently rescues Th1 cytokine production in human whole blood treated by A2A agonists, and increased CD8+ T cell cytotoxicity in a co-culture assay of effector CD8+ T cells and target cancer cells EOS100850 does not penetrate the brain In a mouse lymphoma model, combined with anti-PD-L1, EOS100850 showed significant enhancement of anti-tumoral activities compared with anti-PD-L1 alone Human Anti-TIGIT Antibody (EOS884448): Antagonist antibody against human TIGIT that demonstrates a classical human IgG pharmacokinetics profile. It is currently being evaluated for safety and efficacy in preclinical models with a Phase I trial expected to begin in 2019. Presentation Title: EOS884448 a novel ADCC-Enabling Antibody Targeting TIGIT Restores T Cell Effector Functions and Displays Anti-Tumor Efficacy Date & Time: Wednesday, February 14, 2018 Authors: Grégory Driessens Poster Number: 35 Key Takeaways: EOS884448 binds to human TIGIT and prevents binding of natural ligand at sub-nanomolar concentrations EOS884448 rescues activation of T cells from cancer patients PBMCs and TILs EOS884448 induces preferential depletion of Treg Surrogate mouse a-TIGIT shows potent antitumor efficacy that depends on Ab isotype IDO1 Inhibitor (EOS200271): Synthetic, small molecule inhibitor of indoleamine 2,3-dioxygenase (IDO1) to trigger immune-modulation in the tumor micro-environment. IDO1 inhibitors are one of the most promising immuno-oncology drugs currently in development. This asset is one of five IDO1 inhibitors in clinical development worldwide and EOS200271 is the only IDO1 inhibitor with excellent brain penetration confirmed in patients. EOS200271 is a unique asset and iTeos is evaluating its potential in different indications and combinations with the intention of resuming Phase 1 in 2018. A further update will be provided on clinical development plans in due course.   About iTeos’ Adenosine A2A Receptor Inhibitor (EOS100850) The adenosine A2A receptor is the main adenosine receptor expressed on immune cells, which promotes immune suppression, leading to tumor evasion. iTeos’ best-in-class A2A receptor antagonist, EOS100850, restores T-cell activation inhibited by adenosine. EOS100850 promotes anti-tumor efficacy in mouse tumor models in combination with several immune-checkpoint inhibitors, retains high potency in the presence of elevated intra-tumoral adenosine concentrations, and is non-brain penetrant. EOS100850 is currently being evaluated for safety and efficacy in preclinical models.   About iTeos’ Human Anti-TIGIT Antibody (EOS884448) TIGIT is an immunosuppressive receptor expressed on lymphoid cell populations. TIGIT expression increases in cancer patients and marks exhausted T cells. EOS884448 ­­is an antagonist antibody against human TIGIT. Preclinical studies show its potency to restore T cell function and to preferentially deplete Treg cells in cancer patient material. ADCC/ADCP-enabling isotypes of a-TIGIT surrogate Ab show potent monotherapy efficacy in murine tumor models that correlates to increased T cell activation and reduced Treg infiltration of tumors. EOS884448 demonstrates classical human IgG pharmacokinetics profile and a good developability profile. EOS884448 is currently being evaluated for safety and efficacy in preclinical models.   About iTeos’ IDO1 Inhibitor (EOS200271) EOS200271 is currently in Phase 1 clinical trials, which will be expanded in 2018. The drug candidate is a synthetic, small molecule inhibitor of indoleamine 2,3-dioxygenase (IDO1) that also inhibits IDO1 in the tumor micro-environment to trigger immune-modulation. EOS200271 is distinguished through its high level of brain penetration confirmed in clinical trials. EOS200271 has demonstrated anti-tumor activity in multiple preclinical tumor models in monotherapy and in combination with immune checkpoint inhibitors. EOS200271 was originally licensed from iTeos to Pfizer in December 2014, and was returned to iTeos in 2017.   About iTeos Therapeutics Starting operations in 2012, iTeos Therapeutics is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design.  iTeos is developing EOS200271, a clinical-stage potent and selective IDO1 inhibitor with exceptional brain penetration. The company is also advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase 1 trial in the second half of 2018; and a human ADCC-enabling anti-TIGIT antibody (EOS884448), representing an additional, third clinical entry in 2019. Based in Gosselies, Belgium, iTeos Therapeutics was founded and supported in part by investments from the Ludwig Institute Cancer Research (LICR), the Walloon Region of Belgium and the European Fund for Economic and Regional Development (FEDER). For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com Amber Fennell, Mathew Neal, Hendrik Thys, Suki Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe Stern Investor Relations, Inc. + 1 212 362 1200 sarah@sternir.com